IT systems · Practical guide

Validating Oracle Argus: case identity, follow-up and submission

A follow-up report was imported into Oracle Argus, transmitted and acknowledged. Did it update the correct case and lead to the right processing decision? Check edition, intake configuration, case merge rules and reporting route. The examples help pharmacovigilance, QA and IT trace failures through to the records needed in operation.

Table of contents

At a glance

What do you need to validate in Oracle Argus?

Demonstrate that the Argus configuration supports the intended pharmacovigilance process from the source through case assignment, follow-up and assessment to the correct report and documented receipt. Identify the edition, version, interfaces and responsibilities. Validity of one ICSR and a technical acknowledgement answer different questions from suitability of the entire workflow. Assess supplier evidence against its actual coverage.

  • Argus Safety, Safety One, and the optional Safety One Intake must be separately named within the project scope.
  • A possible duplicate may initially be considered a test candidate; hit results and justified consolidation represent different outcomes.
  • The established case status must remain linked to source, configuration, assessment, and the submitted report version.
  • A technical ACK neither verifies medical accuracy nor confirms the permanent closure of the case processing.

1. Define product variant and pharmacovigilance process

Oracle describes Argus Safety as a core component of both the Standard Edition and Enterprise Edition. Responsibilities include event capture, medical and product-specific coding, assessments, and reports for authorities and partners. The separate Safety One Argus documentation module includes additional intake descriptions. Therefore, a function from this module is not a general commitment applicable to every existing Argus installation.

This article examines pharmacovigilance for authorized human medicinal products in the EU. Clinical trials, medical devices, and other target markets require separate categorization. Furthermore, a pharmaceutical company does not apply all GMP requirements to its safety database solely due to its business model. The key factor is the supported function.

As of October 2026, the EMA identifies the applicable amendments to Regulation (EU) No. 520/2012, as amended by (EU) 2025/1466, together with forthcoming GVP updates driven by ICH E2D(R1) and ICH M14. The older GVP modules should be interpreted in light of these provisions; for ICH E2D(R1), the EMA also refers to its EU Implementation Strategy and supporting documentation. Ensure that the relevant regulatory basis and reporting specification are clearly defined for your project. A previously released template, unchanged from a prior version, does not constitute validation of its current scope.

Sources: [1] [7] [10] [11]

2. Make the process for reporting and clearly define responsibilities

First, describe a real intended input: for example, a partner file or manually recorded information. Who receives the source, who decides on the assignment and who evaluates the case? Also, determine which tasks lie with the marketing authorisation holder, a PV service provider and the technical operator. The agreement must match the actual cooperation.

The following matrix is an internal work aid. For each row, specify the point of contact and a unique reference. A system screenshot with server names is insufficient for this task: it must be demonstrable who identifies a pending report and who resolves a conflicting information issue professionally.

From Source to Report: Scope and Expected Evidence
StageDecision to makeInformation needed
Source and Intake New case, report update, or pending incoming inquiry? Source information, entry channel and assignment basis
Duplicate check Which candidates are being compared? Such configuration, relevant hits and justified decision
Consolidation What is added, corrected, or not carried forward? Source-specific rules, Before/After and Review
Assessment and Report Which version has been technically reviewed and is intended for which recipient? Assessment status, alert configuration, and generated report
Submission and Operation Which procedure was accepted or requires retrospective processing? Message, reception status, error handling and responsible party

Sources: [8] [12] [1]

3. Separate software qualification and individual case validation

The validation of a computerized process assesses whether requirements for the intended use are met. In contrast, the validation of an ICSR evaluates the conditions and quality attributes of each individual safety report. A formally complete case may be processed in an inappropriate configuration. Conversely, correctly functioning software may flag missing information in the input.

Define verifiable process requirements. For example: A follow-up entry must not overwrite information from a second case. The original information must remain accessible for evaluation. An submission status must be correctly associated with the appropriate message and report version. Define what constitutes a deviation and specify who is responsible for determining it.

Map existing supplier and service provider documentation to these requirements. Verify version, tested architecture, and specific coverage. If evidence for your merge rule is missing, precisely extend the evaluation of this area. The existence of a function in the standard neither confirms its correct configuration nor validates its suitability for every partner data pathway. Ambiguities remain visible until assessed or resolved with appropriate evidence.

Sources: [8] [9]

4. Review intake and duplicate searches with distinguishable cases

In the documentation for Safety One Argus 2026.1.01, Consolidated Intake refers to the Intake interface. Safety One Intake, on the other hand, is an additional subscription for AI-driven extraction. Please confirm whether manual entry, structured files, extraction, or multiple methods are being used. For each entry, the source and processed content must be readily identifiable.

The documented duplicate detection for this release can include not only existing cases but also intake data records that have not yet been fully resolved. Weights and thresholds are configurable. Consequently, for the review: a high match rate initially represents a technical search outcome. The professional judgment regarding whether the same person and the same event are intended must be based on appropriate contextual grounds.

Construct a controlled test case comprising a clearly identical case, a similar but distinct case, and a conflicting input. Verify the actually visible information in accordance with the intended roles. Even an authorized restricted operator must understand how to initiate a required identity confirmation. Do not establish a universal search threshold; evaluate misclassifications and missed associations based on your process.

Sources: [3] [4] [12]

5. Treat the merge configuration as a professionally valid change

Oracle documents for version 2026.1.01 an updated follow-up consolidation. The comparison logic can be customized via configuration files and assigned to different intake sources. The Merge Viewer distinguishes proposed additions, modifications, and deletions. Separate takeover strategies are described for large text fields. These capabilities relate to the documented Safety-One context.

Before changing the interface, agree the expected outcome. What does a blank field mean in the partner format? Can a new statement replace an earlier one, or must someone resolve the discrepancy first? What information may the system transfer automatically? The answers depend on the data agreement and what the values mean in the case. A technical comparison alone cannot answer these questions.

Review transition points from previous configurations specifically. Oracle notes that certain prior R2/R3 comparison adjustments are replaced by the new configuration. Customer-specific case identification currently in place is separately highlighted. Therefore, an upgrade may differently impact assignment and subsequent takeover processes. The actual rules prior to and after implementation must be clearly comparable and traceable.

Sources: [5]

6. Test example: A follow-up notification supplements exactly one existing case

The example is not a completed Argus test. In an isolated test environment, cases T-041 and T-042 exist. Only T-041 is documented as linked to incoming record P-700. T-041 includes the example product A and event E1. T-042 has similar search criteria but, according to independently pre-prepared source documentation, is assigned to a different individual.

F-02 Notification to P-700 supplements Product B and Event E2; it explicitly confirms that A and E1 continue to apply. The established target is therefore: T-041 contains subsequently two products and two events, T-042 remains unchanged. These numbers are for use solely in the review of these test data. They provide neither evidence of a medical causality nor a reporting obligation.

Prior to execution, source files, configuration M-02, and target comparison are retained. Personnel must not only justify the final state but also their assignment and transfer decisions. A second variant allows the partner identifier to appear inconsistent; in this case, the example requires documented clarification prior to consolidation.

Expected results for case matching, merging and subsequent processing
Test stepIndependently established expectationSupporting document to be retained
F-02 assign T-041 is the target; T-042 is not overridden despite similarity. Source, match comparison and assignment decision
Accept verified addition A and B as well as E1 and E2 present; a total of two products and two events. Before-and-after comparison with source and configuration M-02
Repeat identical incoming data No unintended second product B or event E2; processing according to established repetition rule. Second entry identifier and documented decision on repetition
Use inconsistent identification labels No undetected blending with T-042; clarification remains visible. Defect finding and traceable further processing
Prepare and transfer Report R-02 Evaluated status and recipient match; ACK corresponds exactly to message N-02. Report version, shipping data, and appropriate receipt response

Sources: [4] [5] [9] [12]

7. Coding, source attribution, and medical review are linked

A dictionary entry and a medical assessment serve distinct functions. The original statement remains the foundation; the structured coding must align with it. Therefore, at appropriate cases, verify that the source statement, coded information, and report text retain the same meaning after processing. A technically valid code alone does not suffice.

For the test case, qualified PV personnel determine the expected output in advance. They also identify which information remains unclear. A test should not compensate for missing information through a seemingly plausible interpretation. Upon subsequent clarification, it must be clearly evident what new information has become available and which prior evaluations require reexamination.

ICH E2D(R1) addresses medical case evaluation and follow-up as distinct responsibilities. Therefore, in addition to technical testing, a business decision-making pathway must be established: Who evaluates the information, who requests targeted clarifications, and how does the response return to the existing case? Validation documentation must neither simulate a medical judgment nor represent a software function as a substitute for such judgment.

Sources: [12] [9] [1]

8. Separate documentation of report, notification, and receipt confirmation

For a submitted report, you require the linkage between the professionally reviewed case status, generated version, recipient, and transmission process. A general indication such as "successfully" may have multiple interpretations. Clarify whether it refers to file generation, transport, or recipient acceptance.

GVP Module VI outlines technical receipt checks using business rules. A positive ACK concludes the respective transmission process; normal follow-up actions proceed with new information. Receipt does not constitute confirmation that an authority has substantively approved the medical evaluation.

Oracle separately describes the download of ACKs for incoming E2B Intake datasets and a configuration-dependent email attachment. Do not confuse this inbound pathway with the receipt confirmation of your outgoing regulatory submission. Verify both directions if they are in use. If a negative or no response is received, it must be clearly visible which process remains open and who is responsible for further processing.

Sources: [9] [10] [6]

9. Manage releases, roles, and historical cases in operation

Here, the specific document version in use is Argus 2026.1.01, April 2026. This does not imply anything about the patch level currently installed on your system. Additionally, capture actual components, glossaries, interface profiles, and technically valid configurations. A different patch level may be relevant to the suitability of existing validation evidence.

Upon a change, identify and mark the affected requirements and data pathways. A new merge rule requires different validation evidence compared to a changed recipient or a simple display adjustment. Existing validation evidence may be reused if its coverage remains justified. Open findings, required retesting, and the decision on usage are considered collectively.

Also assess daily operations: access during absence, controlled changes to rights, availability of historical records, and recovery of required information. A backup agreement does not yet confirm whether your team can thereafter explain an old case—including report and receipt status. Align on outage procedures between PV, IT, and external service providers, and avoid unverified assumptions regarding general retention periods.

Sources: [2] [8] [10]

10. Checklist for project initiation and subsequent usage

The effort primarily depends on various factors: the number and diversity of data sources, legacy customizations, country-specific profiles, historical cases, and shared responsibilities. For a small and medium-sized enterprise (SME), therefore, a limited and well-defined initial scope is more practical than an ambiguous commitment to all possible functionalities. A general project duration cannot be inferred from this.

Plan the workforce engagement specifically: PV defines professional expectations and reporting context; QA supports traceable evidence and finding evaluation; IT and supplier clarify operations and technical configuration. Prior to a usage decision, every relevant open question should be assigned to a responsible party and linked to the next step.

  • Edition, operating mode, release, and actually used intake components specified.
  • Sources, partners, case identifiers, and report recipients with responsible individuals described.
  • Source and merge configuration including source-specific deviations securely preserved.
  • Independent test data prepared for identical, similar, conflicting, and repeated inputs.
  • Technical review, software testing, and technical acceptance as distinct forms of evidence.
  • Roles, escalation, historical accessibility, and failure remediation practically clarified.
  • Supplier invoices assigned; remaining gaps and usage decisions documented.

Sources: [8] [9] [5]

Project experience and collaboration

Trace the safety case through to the correct submission

With Pharmacovigilance and system owners, we follow a prepared case including follow-up, a duplicate link and its intended recipient. We check that the report, start of the reporting clock and technical acknowledgement refer to the right case version. Focused additions to supplier evidence may cover a limited process. Multiple intake and transmission routes need additional comparisons. We support technical validation and evidence. Medical assessment and determination of reporting duties remain with the responsible PV function.

Frequently asked questions about Oracle Argus

Has Oracle Argus been validated by the supplier for our PV process?

Vendor documentation can provide key evidence for documented functions and environments. Verify alignment with your edition, version, and intended use. Custom partner formats, merge rules, roles, and reporting pathways may require additional validation evidence. Therefore, the specific decision is not to either fully adopt or completely retest everything, but rather: Which requirements are already adequately supported, and which remain unverified?

Sources: [8] [1]

Are Argus Safety and Safety One Intake the same product?

No. Argus Safety is the safety incident handling component. The documentation for Safety One Argus refers to the intake interface as Consolidated Intake. Safety One Intake is an additional subscription for AI-assisted extraction. Please confirm the implemented combination including version before adopting any described functionality into your requirements or testing.

Sources: [1] [3]

Which duplicate tests are useful when search thresholds change?

Use known similar cases, analogous dissimilar cases, and deliberately incomplete information. Independently determine which relationships must be evaluated. Compare results before and after the change. A higher recall rate alone is not a success criterion: what matters is whether relevant candidates are identified and false associations are either prevented or detected by the intended decision pathway.

Sources: [4] [12]

What must be verified during the transition to the new follow-up configuration?

Identify prior comparative adjustments and the new assignments by intake source. Review at least the actual affected cases of supplementation, amendment, and conflict. The release documentation distinguishes case identification from replaced comparative mechanisms. Therefore, an unchanged target case alone is not sufficient evidence that all information has been correctly transferred.

Sources: [5]

Does a validated ICSR mean that software validation is complete?

No. The case review pertains to a specific report and its prerequisites or data quality. Software validation relates to the suitability of the intended computerized process. Maintain separate, retrievable evidence for both. A successfully reviewed example case may form part of a software test, but it does not constitute a justified coverage of the relevant requirements and potential failure paths.

Sources: [8] [9]

When is the processing considered complete with a positive ACK?

Interpret the ACK within the relevant exchange and link it to the right message. A positive technical ACK does not indicate medical agreement. New information may require further case processing and a follow-up submission. Distinguish transmission completion, case status and open follow-up actions in procedures and records.

Sources: [9] [12]

Must all historical cases be re-evaluated following an upgrade?

Not at all. Evaluate which data or processing rules change and which existing documents continue to bear. An upgrade with new merge logic may affect other cases than a change in the report layout. Document selection, remaining uncertainty and additional checks. A general reference to the release scope does not replace this impact assessment.

Sources: [5] [8]

What must a PV service provider deliver prior to project start?

Clear responsibilities, relevant procedures, specific system statuses, and traceable evidence of the accepted scope of performance are required. Clarify data transfers, error handling, access controls, and outage contact procedures. The marketing authorization holder needs the information that supports their accountability. A comprehensive document collection without alignment to the actual process is no more effective than a general supplier assurance.

Sources: [8] [12]

How many internal personnel should we assign for validation?

Engage qualified PV personnel for intended behavior and test data, IT for configuration and operational records, and QA for the agreed verification procedure. Significant effort arises particularly when partner data is inconsistent or legacy adaptations are present. Start with a source and variant list; from this, specific work packages and decisions can be derived. A credible time estimate requires this level of detail.

Sources: [8] [5]

Are the same reporting deadlines applicable to each Argus case?

No, there is no globally uniform deadline. For marketing authorization holders in the EU human medicinal product sector, GVP Module VI.C.3 establishes the following framework: serious suspected adverse reaction cases from the EU and non-EU countries must be reported within 15 calendar days; non-serious suspected adverse reaction cases from the EU must be reported within 90 calendar days. The deadline begins upon receipt of the minimum required information, not upon subsequent entry into Argus. Other regions, agreements, and specific scenarios require individual assessment and assignment. Your PV function defines the applicable rules; verify their implementation, including follow-up and technical errors.

Sources: [12] [10] [11]

Sources and review date

Source date: 6 October 2026. Product details are based on the specifically referenced Oracle documentation; the deployed edition and configuration must be independently verified. GVP modules are classified in conjunction with current EMA guidance and ICH E2D(R1). Tables and case example are standalone review aids and do not constitute completed product testing.

  1. Oracle Argus Safety Documentation
  2. Oracle Life Sciences Argus – What’s New, Release 2026.1.01
  3. Safety One Argus 2026.1.01 – What’s new in Consolidated Intake
  4. Oracle Safety One Argus: Follow-up merge enhancements
  5. Oracle Safety One Argus: E2B Intake Acknowledgment enhancements
  6. EMA: Good pharmacovigilance practices (GVP)
  7. GVP Module I: Pharmacovigilance systems and their quality systems
  8. GVP Module VI: Collection, management and submission of reports of suspected adverse reactions, Rev. 2
  9. EMA: EudraVigilance – electronic reporting
  10. EMA: ICH E2D post-approval safety data management – Scientific guideline
  11. ICH E2D(R1): Post-Approval Safety Data – Definitions and Standards for Management and Reporting of Individual Case Safety Reports

Sources checked: .

Daniel Herrmann, Daniel Herrmann Consulting

Daniel Herrmann Consulting

Integrate the Argus process and its associated documentation.

Daniel Herrmann Consulting supports you in aligning technical validation with the requirements of your PV function and existing supplier evidence.

  • Computer system validation →

    Bring your GxP systems into validated operation, from laboratory software, MES and eQMS to ERP. We define the scope, plan risk-based tests using GAMP 5 and hand the evidence to QA for release.

Send a project enquiry Customer testimonials →